Simple blood test may predict prostate cancer radiation risks
NCT ID NCT07145437
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a blood test, called the RILA assay, can predict which prostate cancer patients will have late side effects from a precise type of radiation therapy (SBRT). About 220 men with low- or intermediate-risk prostate cancer will give a blood sample before treatment and be followed for 5 years. The goal is to personalize treatment and reduce severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radio-induced Lymphocyte Apoptosis (RILA) Assay
What this could lead to
If successful, this blood test could help doctors identify which prostate cancer patients are at higher risk for side effects from radiation, allowing for more personalized and safer treatment plans.
What could go wrong
This is an early-stage study focused on prediction, not treatment. The test may not accurately predict side effects in all patients, and results may not change outcomes directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••